82 results
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
of their fiduciary duties. They may also reduce the likelihood of derivative litigation against the registrant’s directors and executive officers
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
as have been obtained.
(q) There is no judicial, regulatory, arbitral or other legal or governmental proceeding or other litigation or arbitration … obligations hereunder; to the Company’s knowledge, no such proceeding, litigation or arbitration is threatened or contemplated; and the defense of all
8-K
EX-10.1
5cg8szzg9ln
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.2
fh0u99c6t4bn3otdir2f
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
612w3246ppofh5z9l3sp
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
ejl78ks
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-10.1
dl4phbb
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-1.1
lho1mybh
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
qaw00
30 Mar 22
Prospectus supplement for primary offering
5:21pm